{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:20:09Z","timestamp":1793380809082,"version":"4.5.0"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02645-6","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:45:23Z","timestamp":1741754723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications"],"prefix":"10.1186","volume":"22","author":[{"given":"Kai Yuan","family":"Leong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Kong","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chit Laa","family":"Poh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"12","key":"2645_CR1","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/vaccines9121490","volume":"9","author":"M Ghattas","year":"2021","unstructured":"Ghattas M, Dwivedi G, Lavertu M, Alameh M-G. Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities. Vaccines. 2021;9(12):1490.","journal-title":"Vaccines"},{"issue":"3","key":"2645_CR2","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2645_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3390\/vaccines12080873","volume":"12","author":"Z Wu","year":"2024","unstructured":"Wu Z, Sun W, Qi H. Recent advancements in mRNA vaccines: from target selection to delivery systems. Vaccines. 2024;12(8):873.","journal-title":"Vaccines"},{"issue":"16","key":"2645_CR4","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39(16):2190\u2013200.","journal-title":"Vaccine"},{"issue":"4","key":"2645_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12272-022-01381-7","volume":"45","author":"S Kwon","year":"2022","unstructured":"Kwon S, Kwon M, Im S, Lee K, Lee H. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Arch Pharmacal Res. 2022;45(4):245\u201362.","journal-title":"Arch Pharmacal Res"},{"key":"2645_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/srep00126","author":"S Kruse","year":"2011","unstructured":"Kruse S, Zhong S, Bodi Z, Button J, Alcocer MJC, Hayes CJ, et al. A novel synthesis and detection method for cap-associated adenosine modifications in mouse mRNA. Sci Rep. 2011. https:\/\/doi.org\/10.1038\/srep00126.","journal-title":"Sci Rep"},{"issue":"16","key":"2645_CR7","doi-asserted-by":"publisher","first-page":"7511","DOI":"10.1093\/nar\/gkw551","volume":"44","author":"A Ramanathan","year":"2016","unstructured":"Ramanathan A, Robb GB, Chan S-H. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511\u201326. https:\/\/doi.org\/10.1093\/nar\/gkw551.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"2645_CR8","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1002\/cpz1.39","volume":"1","author":"JM Henderson","year":"2021","unstructured":"Henderson JM, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N, et al. Cap 1 messenger RNA synthesis with co-transcriptional CleanCap\u00ae analog by in vitro transcription. Curr Protoc. 2021;1(2):e39.","journal-title":"Curr Protoc"},{"issue":"1","key":"2645_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41420-020-00358-z","volume":"6","author":"A Paramasivam","year":"2020","unstructured":"Paramasivam A. RNA 2\u2032-O-methylation modification and its implication in COVID-19 immunity. Cell Death Discov. 2020;6(1):118.","journal-title":"Cell Death Discov."},{"issue":"1","key":"2645_CR10","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1038\/s41467-023-38244-8","volume":"14","author":"M Inagaki","year":"2023","unstructured":"Inagaki M, Abe N, Li Z, Nakashima Y, Acharyya S, Ogawa K, et al. Cap analogs with a hydrophobic photocleavable tag enable facile purification of fully capped mRNA with various cap structures. Nat Commun. 2023;14(1):2657.","journal-title":"Nat Commun"},{"issue":"12","key":"2645_CR11","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.1021\/jacs.3c12629","volume":"146","author":"M Warminski","year":"2024","unstructured":"Warminski M, Trepkowska E, Smietanski M, Sikorski PJ, Baranowski MR, Bednarczyk M, et al. Trinucleotide mRNA cap analogue N6-benzylated at the site of posttranscriptional m6Am mark facilitates mRNA purification and confers superior translational properties in vitro and in vivo. J Am Chem Soc. 2024;146(12):8149\u201363.","journal-title":"J Am Chem Soc"},{"issue":"5","key":"2645_CR12","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/febs.12115","volume":"280","author":"S Chulakasian","year":"2013","unstructured":"Chulakasian S, Chang T, Tsai C, Wong M, Hsu W. Translational enhancing activity in 5\u2032 UTR of peste des petits ruminants virus fusion gene. FEBS J. 2013;280(5):1237\u201348. https:\/\/doi.org\/10.1111\/febs.12115.","journal-title":"FEBS J"},{"issue":"3","key":"2645_CR13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/nrm.2017.103","volume":"19","author":"K Leppek","year":"2018","unstructured":"Leppek K, Das R, Barna M. Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them. Nat Rev Mol Cell Biol. 2018;19(3):158\u201374.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2645_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.omtn.2021.10.007","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2021","unstructured":"Linares-Fern\u00e1ndez S, Moreno J, Lambert E, Mercier-Gouy P, Vachez L, Verrier B, et al. Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA. Mol Ther Nucleic Acids. 2021;26:945\u201356.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"2645_CR15","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/vaccines11101600","volume":"11","author":"AD Perenkov","year":"2023","unstructured":"Perenkov AD, Sergeeva AD, Vedunova MV, Krysko DV. In vitro transcribed RNA-based platform vaccines: past, present, and future. Vaccines. 2023;11(10):1600.","journal-title":"Vaccines"},{"issue":"6292","key":"2645_CR16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1126\/science.aad9868","volume":"352","author":"AG Hinnebusch","year":"2016","unstructured":"Hinnebusch AG, Ivanov IP, Sonenberg N. Tranlational control by 5\u2019-untranslated regions of eukaryotic mRNAs. Science. 2016;352(6292):1413\u20136.","journal-title":"Science"},{"issue":"4","key":"2645_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","volume":"136","author":"N Sonenberg","year":"2009","unstructured":"Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731\u201345. https:\/\/doi.org\/10.1016\/j.cell.2009.01.042.","journal-title":"Cell"},{"issue":"1","key":"2645_CR18","doi-asserted-by":"publisher","first-page":"19845","DOI":"10.1038\/s41598-024-70792-x","volume":"14","author":"Q Ma","year":"2024","unstructured":"Ma Q, Zhang X, Yang J, Li H, Hao Y, Feng X. Optimization of the 5\u02b9 untranslated region of mRNA vaccines. Sci Rep. 2024;14(1):19845.","journal-title":"Sci Rep"},{"issue":"4","key":"2645_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ymthe.2018.12.011","volume":"27","author":"AG Orlandini Von Niessen","year":"2019","unstructured":"Orlandini Von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3\u2032 UTRs identified by cellular library screening. Mol Ther. 2019;27(4):824\u201336. https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.011.","journal-title":"Mol Ther"},{"issue":"13","key":"2645_CR20","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","volume":"108","author":"S Holtkamp","year":"2006","unstructured":"Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009\u201317. https:\/\/doi.org\/10.1182\/blood-2006-04-015024.","journal-title":"Blood"},{"issue":"1","key":"2645_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/vaccines8010123","volume":"8","author":"X Zhuang","year":"2020","unstructured":"Zhuang X, Qi Y, Wang M, Yu N, Nan F, Zhang H, et al. mRNA vaccines encoding the HA protein of influenza A H1N1 virus delivered by cationic lipid nanoparticles induce protective immune responses in mice. Vaccines. 2020;8(1):123.","journal-title":"Vaccines"},{"issue":"7893","key":"2645_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-04231-6","volume":"601","author":"MS Gebre","year":"2022","unstructured":"Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, et al. Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature. 2022;601(7893):410\u20134.","journal-title":"Nature"},{"issue":"8","key":"2645_CR23","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.3390\/vaccines10081251","volume":"10","author":"N Roth","year":"2022","unstructured":"Roth N, Sch\u00f6n J, Hoffmann D, Thran M, Thess A, Mueller SO, et al. Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homologous and heterologous neutralising antibody responses. Vaccines. 2022;10(8):1251.","journal-title":"Vaccines"},{"issue":"1","key":"2645_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94.","journal-title":"Signal Transduct Target Ther"},{"key":"2645_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601: 120586.","journal-title":"Int J Pharm"},{"issue":"1","key":"2645_CR26","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1038\/s41467-024-51301-0","volume":"15","author":"J Monroe","year":"2024","unstructured":"Monroe J, Eyler DE, Mitchell L, Deb I, Bojanowski A, Srinivas P, et al. N1-Methylpseudouridine and pseudouridine modifications modulate mRNA decoding during translation. Nat Commun. 2024;15(1):8119.","journal-title":"Nat Commun"},{"issue":"11","key":"2645_CR27","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/mt.2008.200","volume":"16","author":"K Karik\u00f3","year":"2008","unstructured":"Karik\u00f3 K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833\u201340. https:\/\/doi.org\/10.1038\/mt.2008.200.","journal-title":"Mol Ther"},{"issue":"20","key":"2645_CR28","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/nar\/gkac719","volume":"50","author":"J Hertler","year":"2022","unstructured":"Hertler J, Slama K, Schober B, \u00d6zrendeci Z, Marchand V, Motorin Y, et al. Synthesis of point-modified mRNA. Nucleic Acids Res. 2022;50(20):e115.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2645_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","volume":"180","author":"S Kreiter","year":"2008","unstructured":"Kreiter S, Selmi A, Diken M, Sebastian M, Osterloh P, Schild H, et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol. 2008;180(1):309\u201318.","journal-title":"J Immunol"},{"key":"2645_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.omtn.2022.10.003","volume":"30","author":"CY Li","year":"2022","unstructured":"Li CY, Liang Z, Hu Y, Zhang H, Setiasabda KD, Li J, et al. Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in vivo. Mol Ther Nucleic Acids. 2022;30:300\u201310.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"2645_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/vaccines10111807","volume":"10","author":"J Li","year":"2022","unstructured":"Li J, Liu Q, Liu J, Fang Z, Luo L, Li S, et al. Development of bivalent mRNA vaccines against SARS-CoV-2 variants. Vaccines. 2022;10(11):1807.","journal-title":"Vaccines"},{"issue":"1","key":"2645_CR32","doi-asserted-by":"publisher","first-page":"e1737","DOI":"10.1002\/wrna.1737","volume":"14","author":"A Brouze","year":"2023","unstructured":"Brouze A, Krawczyk PS, Dziembowski A, Mroczek S. Measuring the tail: methods for poly(A) tail profiling. WIREs RNA. 2023;14(1):e1737.","journal-title":"WIREs RNA"},{"key":"2645_CR33","doi-asserted-by":"publisher","first-page":"885371","DOI":"10.3389\/fimmu.2022.885371","volume":"13","author":"RJ Ladak","year":"2022","unstructured":"Ladak RJ, He AJ, Huang Y-H, Ding Y. The current landscape of mRNA vaccines against viruses and cancer\u2014a mini review. Front Immunol. 2022;13:885371.","journal-title":"Front Immunol"},{"issue":"6","key":"2645_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17488","volume":"9","author":"TC Ezike","year":"2023","unstructured":"Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, et al. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023;9(6): e17488.","journal-title":"Heliyon"},{"issue":"1","key":"2645_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40824-023-00425-3","volume":"27","author":"M Yuan","year":"2023","unstructured":"Yuan M, Han Z, Liang Y, Sun Y, He B, Chen W, et al. mRNA nanodelivery systems: targeting strategies and administration routes. Biomater Res. 2023;27(1):90.","journal-title":"Biomater Res."},{"issue":"1","key":"2645_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1477-3155-9-55","volume":"9","author":"A Mahapatro","year":"2011","unstructured":"Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol. 2011;9(1):55.","journal-title":"J Nanobiotechnol"},{"issue":"19","key":"2645_CR37","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.3390\/molecules26195905","volume":"26","author":"S Adepu","year":"2021","unstructured":"Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19):5905.","journal-title":"Molecules"},{"issue":"05","key":"2645_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4236\/jbnb.2011.225062","volume":"02","author":"N Martinho","year":"2011","unstructured":"Martinho N, Damg\u00e9 C, Reis CP. Recent advances in drug delivery systems. J Biomater Nanobiotechnol. 2011;02(05):510\u201326.","journal-title":"J Biomater Nanobiotechnol"},{"issue":"10","key":"2645_CR39","doi-asserted-by":"publisher","first-page":"4105","DOI":"10.1016\/j.apsb.2022.11.026","volume":"13","author":"W Zhang","year":"2023","unstructured":"Zhang W, Jiang Y, He Y, Boucetta H, Wu J, Chen Z, et al. Lipid carriers for mRNA delivery. Acta Pharmaceutica Sinica B. 2023;13(10):4105\u201326.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"2645_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114895","volume":"198","author":"P Wen","year":"2023","unstructured":"Wen P, Ke W, Dirisala A, Toh K, Tanaka M, Li J. Stealth and pseudo-stealth nanocarriers. Adv Drug Deliv Rev. 2023;198: 114895.","journal-title":"Adv Drug Deliv Rev"},{"issue":"01","key":"2645_CR41","first-page":"69","volume":"04","author":"A Srivastava","year":"2016","unstructured":"Srivastava A, Yadav T, Sharma S, Nayak A, Akanksha Kumari A, Mishra N. Polymers in drug delivery. J Biosci Med. 2016;04(01):69\u201384.","journal-title":"J Biosci Med"},{"issue":"5","key":"2645_CR42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","volume":"22","author":"FM Veronese","year":"2008","unstructured":"Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315\u201329.","journal-title":"BioDrugs"},{"issue":"16","key":"2645_CR43","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.3390\/molecules25163731","volume":"25","author":"A Zieli\u0144ska","year":"2020","unstructured":"Zieli\u0144ska A, Carreir\u00f3 F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731.","journal-title":"Molecules"},{"key":"2645_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.4103\/2278-344X.107832","volume":"1","author":"N Jawahar","year":"2012","unstructured":"Jawahar N, Meyyanathan SN. Polymeric nanoparticles for drug delivery and targeting: a comprehensive review. Int J Health Allied Sci. 2012;1:217.","journal-title":"Int J Health Allied Sci."},{"issue":"5","key":"2645_CR45","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/pharmaceutics15051502","volume":"15","author":"X Cai","year":"2023","unstructured":"Cai X, Dou R, Guo C, Tang J, Li X, Chen J, et al. Cationic polymers as transfection reagents for nucleic acid delivery. Pharmaceutics. 2023;15(5):1502.","journal-title":"Pharmaceutics"},{"issue":"3","key":"2645_CR46","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377\u201397. https:\/\/doi.org\/10.3390\/polym3031377.","journal-title":"Polymers"},{"issue":"8","key":"2645_CR47","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/polym12081656","volume":"12","author":"V Tkachenko","year":"2020","unstructured":"Tkachenko V, Vidal L, Josien L, Schmutz M, Poly J, Chemtob A. Characterizing the core\u2013shell architecture of block copolymer nanoparticles with electron microscopy: a multi-technique approach. Polymers. 2020;12(8):1656.","journal-title":"Polymers"},{"issue":"8","key":"2645_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/pj.2015.35","volume":"47","author":"K Numata","year":"2015","unstructured":"Numata K. Poly(amino acid)s\/polypeptides as potential functional and structural materials. Polym J. 2015;47(8):537\u201345.","journal-title":"Polym J"},{"key":"2645_CR49","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/B978-0-08-101750-0.00007-6","volume-title":"Engineering of biomaterials for drug delivery systems","author":"M Khuphe","year":"2018","unstructured":"Khuphe M, Thornton PD. 7. Poly(amino acids). In: Parambath A, editor. Engineering of biomaterials for drug delivery systems. Cambridge: Woodhead Publishing; 2018. p. 199\u2013228."},{"issue":"8","key":"2645_CR50","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/pharmaceutics13081291","volume":"13","author":"D Sivadasan","year":"2021","unstructured":"Sivadasan D, Sultan MH, Madkhali O, Almoshari Y, Thangavel N. Polymeric lipid hybrid nanoparticles (PLNs) as emerging drug delivery platform\u2014a comprehensive review of their properties, preparation methods, and therapeutic applications. Pharmaceutics. 2021;13(8):1291.","journal-title":"Pharmaceutics"},{"issue":"8","key":"2645_CR51","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3390\/pharmaceutics15082042","volume":"15","author":"HB Koh","year":"2023","unstructured":"Koh HB, Kim HJ, Kang S-W, Yoo T-H. Exosome-based drug delivery: translation from bench to clinic. Pharmaceutics. 2023;15(8):2042.","journal-title":"Pharmaceutics"},{"key":"2645_CR52","first-page":"183","volume-title":"Advances in protein chemistry and structural biology","author":"Y He","year":"2018","unstructured":"He Y, Li F, Huang Y. Chapter Six. Smart cell-penetrating peptide-based techniques for intracellular delivery of therapeutic macromolecules. In: Donev R, editor. Advances in protein chemistry and structural biology, vol. 112. New York: Academic Press; 2018. p. 183\u2013220."},{"key":"2645_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115115","volume":"203","author":"TI Janjua","year":"2023","unstructured":"Janjua TI, Cao Y, Kleitz F, Linden M, Yu C, Popat A. Silica nanoparticles: a review of their safety and current strategies to overcome biological barriers. Adv Drug Deliv Rev. 2023;203: 115115.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"2645_CR54","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1586\/14760584.2015.973859","volume":"14","author":"D Weissman","year":"2015","unstructured":"Weissman D. mRNA transcript therapy. Expert Rev Vaccines. 2015;14(2):265\u201381.","journal-title":"Expert Rev Vaccines"},{"issue":"6572","key":"2645_CR55","doi-asserted-by":"publisher","first-page":"abm0829","DOI":"10.1126\/science.abm0829","volume":"374","author":"RR Goel","year":"2021","unstructured":"Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829.","journal-title":"Science"},{"issue":"7870","key":"2645_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","volume":"596","author":"JS Turner","year":"2021","unstructured":"Turner JS, O\u2019Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature. 2021;596(7870):109\u201313.","journal-title":"Nature"},{"issue":"1","key":"2645_CR57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/imr.12741","volume":"288","author":"SA Jenks","year":"2019","unstructured":"Jenks SA, Cashman KS, Woodruff MC, Lee FE, Sanz I. Extrafollicular responses in humans and SLE. Immunol Rev. 2019;288(1):136\u201348.","journal-title":"Immunol Rev"},{"issue":"9","key":"2645_CR58","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00018-011-0657-y","volume":"68","author":"EJAM Sijts","year":"2011","unstructured":"Sijts EJAM, Kloetzel P-M. The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci. 2011;68(9):1491\u2013502. https:\/\/doi.org\/10.1007\/s00018-011-0657-y.","journal-title":"Cell Mol Life Sci"},{"issue":"21","key":"2645_CR59","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1128\/MCB.00738-08","volume":"28","author":"Y Martineau","year":"2008","unstructured":"Martineau Y, Derry MC, Wang X, Yanagiya A, Berlanga JJ, Shyu A-B, et al. Poly(A)-binding protein-interacting protein 1 binds to eukaryotic translation initiation factor 3 to stimulate translation. Mol Cell Biol. 2008;28(21):6658\u201367.","journal-title":"Mol Cell Biol"},{"issue":"8","key":"2645_CR60","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/biom14081036","volume":"14","author":"N Parvin","year":"2024","unstructured":"Parvin N, Joo SW, Mandal TK. Enhancing vaccine efficacy and stability: a review of the utilization of nanoparticles in mRNA vaccines. Biomolecules. 2024;14(8):1036.","journal-title":"Biomolecules"},{"issue":"1","key":"2645_CR61","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coi.2012.01.007","volume":"24","author":"S Apcher","year":"2012","unstructured":"Apcher S, Manoury B, F\u00e5hraeus R. The role of mRNA translation in direct MHC class I antigen presentation. Curr Opin Immunol. 2012;24(1):71\u20136.","journal-title":"Curr Opin Immunol"},{"key":"2645_CR62","unstructured":"World Health Organization: WHO R&D Blueprint Team. https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines (2023). Accessed 13 Dec 2024."},{"issue":"5","key":"2645_CR63","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2533\/chimia.2019.391","volume":"73","author":"M Tusup","year":"2019","unstructured":"Tusup M, French LE, De Matos M, Gatfield D, Kundig T, Pascolo S. Design of in vitro transcribed mRNA vectors for research and therapy. Chimia. 2019;73(5):391.","journal-title":"Chimia"},{"key":"2645_CR64","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.biomaterials.2017.11.034","volume":"156","author":"H Kwon","year":"2018","unstructured":"Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee K, et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials. 2018;156:172\u201393.","journal-title":"Biomaterials"},{"issue":"21","key":"2645_CR65","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","volume":"39","author":"K Karik\u00f3","year":"2011","unstructured":"Karik\u00f3 K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39(21):e142. https:\/\/doi.org\/10.1093\/nar\/gkr695.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2645_CR66","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1261\/rna.5264804","volume":"10","author":"PJ Lukavsky","year":"2004","unstructured":"Lukavsky PJ, Puglisi JD. Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides. RNA. 2004;10(5):889\u201393. https:\/\/doi.org\/10.1261\/rna.5264804.","journal-title":"RNA"},{"issue":"12","key":"2645_CR67","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1038\/nprot.2007.480","volume":"2","author":"SA McKenna","year":"2007","unstructured":"McKenna SA, Kim I, Puglisi EV, Lindhout DA, Aitken CE, Marshall RA, et al. Purification and characterization of transcribed RNAs using gel filtration chromatography. Nat Protoc. 2007;2(12):3270\u20137.","journal-title":"Nat Protoc"},{"issue":"14","key":"2645_CR68","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1007\/s00216-018-0943-8","volume":"410","author":"L Baronti","year":"2018","unstructured":"Baronti L, Karlsson H, Maru\u0161i\u010d M, Petzold K. A guide to large-scale RNA sample preparation. Anal Bioanal Chem. 2018;410(14):3239\u201352. https:\/\/doi.org\/10.1007\/s00216-018-0943-8.","journal-title":"Anal Bioanal Chem"},{"key":"2645_CR69","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer M, Boros G, Muramatsu H, Mahiny A, Vlatkovic I, Sahin U, et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids. 2019;15:26\u201335. https:\/\/doi.org\/10.1016\/j.omtn.2019.02.018.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"2645_CR70","doi-asserted-by":"publisher","first-page":"pdb-prot101733","DOI":"10.1101\/pdb.prot101733","volume":"2019","author":"MR Green","year":"2019","unstructured":"Green MR, Sambrook J. Isolation of poly(A)(+) messenger RNA using magnetic oligo(dT) beads. Cold Spring Harb Protoc. 2019;2019(10):pdb-prot101733.","journal-title":"Cold Spring Harb Protoc"},{"issue":"2","key":"2645_CR71","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jiph.2021.12.014","volume":"15","author":"JA Malik","year":"2022","unstructured":"Malik JA, Ahmed S, Mir A, Shinde M, Bender O, Alshammari F, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health. 2022;15(2):228\u201340.","journal-title":"J Infect Public Health"},{"key":"2645_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109762","volume":"255","author":"K F\u00f6hse","year":"2023","unstructured":"F\u00f6hse K, Geckin B, Zoodsma M, Kilic G, Liu Z, R\u00f6ring RJ, et al. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses. Clin Immunol. 2023;255: 109762.","journal-title":"Clin Immunol"},{"issue":"7","key":"2645_CR73","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/vaccines12070714","volume":"12","author":"M Kumari","year":"2024","unstructured":"Kumari M, Liang K-H, Su S-C, Lin H-T, Lu Y-F, Wu M-J, et al. Multivalent mRNA vaccine elicits broad protection against SARS-CoV-2 variants of concern. Vaccines. 2024;12(7):714.","journal-title":"Vaccines"},{"issue":"12","key":"2645_CR74","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.1097\/MS9.0000000000001386","volume":"85","author":"S Yadav","year":"2023","unstructured":"Yadav S, Zaman K, Bashyal P, Bhatta R, Bhandari S, Mohanty A, et al. Newer emerging SARS-COV2 variant: omicron EG5. Ann Med Surg. 2023;85(12):5845\u20136.","journal-title":"Ann Med Surg."},{"issue":"7","key":"2645_CR75","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn AW, RamosDaSilva J, Rosado VC, Bliss CM, Pine M, Mui BL, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol Ther. 2020;28(7):1569\u201384.","journal-title":"Mol Ther"},{"issue":"50","key":"2645_CR76","doi-asserted-by":"publisher","first-page":"eadc9937","DOI":"10.1126\/sciadv.adc9937","volume":"8","author":"K Van Ven","year":"2022","unstructured":"Van Ven K, Lanfermeijer J, Van Dijken H, Muramatsu H, Vilas Boas De Melo C, Lenz S, et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci Adv. 2022;8(50):eadc9937.","journal-title":"Sci Adv"},{"issue":"6622","key":"2645_CR77","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo CP, Bolton MJ, Le Sage V, Ye N, Furey C, Muramatsu H, et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science. 2022;378(6622):899\u2013904.","journal-title":"Science"},{"issue":"7","key":"2645_CR78","first-page":"e41717","volume":"15","author":"S Soni","year":"2023","unstructured":"Soni S, Gill VJS, Anusheel, Singh J, Chhabra J, Gill GJS, et al. Dengue, Chikungunya, and Zika: The causes and threats of emerging and re-emerging arboviral diseases. Cureus. 2023;15(7):e41717","journal-title":"Cureus"},{"issue":"9","key":"2645_CR79","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiaa761","volume":"225","author":"E L\u00f3pez-Medina","year":"2022","unstructured":"L\u00f3pez-Medina E, Biswal S, Saez-Llorens X, Borja-Tabora C, Bravo L, Sirivichayakul C, et al. Efficacy of a dengue vaccine candidate (TAK-003) in healthy children and adolescents 2 years after vaccination. J Infect Dis. 2022;225(9):1521\u201332.","journal-title":"J Infect Dis"},{"issue":"2","key":"2645_CR80","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","volume":"12","author":"V Tricou","year":"2024","unstructured":"Tricou V, Yu D, Reynales H, Biswal S, Saez-Llorens X, Sirivichayakul C, et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2024;12(2):e257\u201370.","journal-title":"Lancet Glob Health"},{"key":"2645_CR81","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","volume":"18","author":"M Zhang","year":"2020","unstructured":"Zhang M, Sun J, Li M, Jin X. Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Mol Ther Methods Clin Dev. 2020;18:702\u201312.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"2645_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.02482-20","volume":"95","author":"CJ Wollner","year":"2021","unstructured":"Wollner CJ, Richner M, Hassert MA, Pinto AK, Brien JD, Richner JM. A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses. J Virol. 2021;95(12):10\u20131128.","journal-title":"J Virol"},{"key":"2645_CR83","doi-asserted-by":"crossref","unstructured":"Stewart-Jones GBE, Elbashir SM, Wu K, Lee D, Renzi I, Ying B, et al. Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains. 2022.","DOI":"10.1101\/2022.10.07.511319"},{"issue":"5","key":"2645_CR84","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.virs.2022.07.003","volume":"37","author":"L He","year":"2022","unstructured":"He L, Sun W, Yang L, Liu W, Li J. A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice. Virologica Sinica. 2022;37(5):746\u201357.","journal-title":"Virologica Sinica"},{"issue":"11","key":"2645_CR85","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.cell.2023.04.024","volume":"186","author":"MAG Hoffmann","year":"2023","unstructured":"Hoffmann MAG, Yang Z, Huey-Tubman KE, Cohen AA, Gnanapragasam PNP, Nakatomi LM, et al. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell. 2023;186(11):2380-91.e9.","journal-title":"Cell"},{"key":"2645_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/ITT.S241064","volume":"9","author":"AN Oli","year":"2020","unstructured":"Oli AN, Obialor WO, Ifeanyichukwu MO, Odimegwu DC, Okoyeh JN, Emechebe GO, et al. Immunoinformatics and vaccine development: an overview. ImmunoTargets Ther. 2020;9:13\u201330.","journal-title":"ImmunoTargets Ther"},{"issue":"5","key":"2645_CR87","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/v15051120","volume":"15","author":"N Rcheulishvili","year":"2023","unstructured":"Rcheulishvili N, Mao J, Papukashvili D, Feng S, Liu C, Yang X, et al. Development of a multi-epitope universal mRNA vaccine candidate for monkeypox, smallpox, and vaccinia viruses: design and in silico analyses. Viruses. 2023;15(5):1120.","journal-title":"Viruses"},{"key":"2645_CR88","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijbiomac.2022.12.066","volume":"226","author":"N Rcheulishvili","year":"2023","unstructured":"Rcheulishvili N, Mao J, Papukashvili D, Liu C, Wang Z, Zhao J, et al. Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic\/pandemic preparedness. Int J Biol Macromol. 2023;226:885\u201399.","journal-title":"Int J Biol Macromol"},{"issue":"20","key":"2645_CR89","doi-asserted-by":"publisher","first-page":"13054","DOI":"10.3390\/ijerph192013054","volume":"19","author":"HN Althurwi","year":"2022","unstructured":"Althurwi HN, Alharthy KM, Albaqami FF, Altharawi A, Javed MR, Muhseen ZT, et al. mRNA-based vaccine designing against Epstein-Barr virus to induce an immune response using immunoinformatic and molecular modelling approaches. Int J Environ Res Public Health. 2022;19(20):13054.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"2645_CR90","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41598-024-84823-0","volume":"15","author":"S Ma","year":"2025","unstructured":"Ma S, Zhu F, Zhang P, Xu Y, Zhou Z, Yang H, et al. Development of a novel multi-epitope subunit mRNA vaccine candidate to combat Acinetobacter baumannii. Sci Rep. 2025;15(1):1410.","journal-title":"Sci Rep"},{"issue":"12","key":"2645_CR91","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.3390\/vaccines10122107","volume":"10","author":"EK Oladipo","year":"2022","unstructured":"Oladipo EK, Adeniyi MO, Ogunlowo MT, Irewolede BA, Adekanola VO, Oluseyi GS, et al. Bioinformatics designing and molecular modelling of a universal mRNA vaccine for SARS-CoV-2 infection. Vaccines. 2022;10(12):2107.","journal-title":"Vaccines"},{"issue":"22","key":"2645_CR92","doi-asserted-by":"publisher","first-page":"13911","DOI":"10.3390\/ijms232213911","volume":"23","author":"M Mukhtar","year":"2022","unstructured":"Mukhtar M, Wajeeha AW, Zaidi NUSS, Bibi N. Engineering modified mRNA-based vaccine against dengue virus using computational and reverse vaccinology approaches. Int J Mol Sci. 2022;23(22):13911.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2645_CR93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s12026-023-09429-6","volume":"72","author":"AA Alsaiari","year":"2024","unstructured":"Alsaiari AA, Hakami MA, Alotaibi BS, Alkhalil SS, Hazazi A, Alkhorayef N, et al. Rational design of multi-epitope-based vaccine by exploring all dengue virus serotypes proteome: an immunoinformatic approach. Immunol Res. 2024;72(2):242\u201359.","journal-title":"Immunol Res"},{"issue":"9","key":"2645_CR94","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/biology13090681","volume":"13","author":"H Ullah","year":"2024","unstructured":"Ullah H, Ullah S, Li J, Yang F, Tan L. An in silico design of a vaccine against all serotypes of the dengue virus based on virtual screening of B-cell and T-cell epitopes. Biology. 2024;13(9):681.","journal-title":"Biology"},{"issue":"2","key":"2645_CR95","doi-asserted-by":"publisher","first-page":"156","DOI":"10.7774\/cevr.2023.12.2.156","volume":"12","author":"LR Herrera-Ong","year":"2023","unstructured":"Herrera-Ong LR. Strategic construction of mRNA vaccine derived from conserved and experimentally validated epitopes of avian influenza type A virus: a reverse vaccinology approach. Clin Exp Vaccine Res. 2023;12(2):156.","journal-title":"Clin Exp Vaccine Res"},{"issue":"10","key":"2645_CR96","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","volume":"55","author":"Y Lee","year":"2023","unstructured":"Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Exp Mol Med. 2023;55(10):2085\u201396.","journal-title":"Exp Mol Med"},{"issue":"4","key":"2645_CR97","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/imm.13443","volume":"165","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xu Z, Wang P, Li X, Shuai Z, Ye D, et al. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology. 2022;165(4):386\u2013401.","journal-title":"Immunology"},{"issue":"3","key":"2645_CR98","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.ymthe.2021.01.030","volume":"29","author":"SM Moghimi","year":"2021","unstructured":"Moghimi SM. Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines. Mol Ther. 2021;29(3):898\u2013900.","journal-title":"Mol Ther"},{"issue":"31","key":"2645_CR99","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1016\/j.vaccine.2023.06.009","volume":"41","author":"GT Kozma","year":"2023","unstructured":"Kozma GT, M\u00e9sz\u00e1ros T, Ber\u00e9nyi P, Facsk\u00f3 R, Patk\u00f3 Z, Ol\u00e1h CZ, et al. Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: evidence for immunogenicity of PEG. Vaccine. 2023;41(31):4561\u201370.","journal-title":"Vaccine"},{"key":"2645_CR100","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.jvacx.2024.100497","volume":"19","author":"BA Barta","year":"2024","unstructured":"Barta BA, Radovits T, Dobos AB, Tibor Kozma G, M\u00e9sz\u00e1ros T, Ber\u00e9nyi P, et al. Comirnaty-induced cardiopulmonary distress and other symptoms of complement-mediated pseudo-anaphylaxis in a hyperimmune pig model: Causal role of anti-PEG antibodies. Vaccine X. 2024;19:100497.","journal-title":"Vaccine X."},{"key":"2645_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","volume":"48","author":"BZ Igy\u00e1rt\u00f3","year":"2021","unstructured":"Igy\u00e1rt\u00f3 BZ, Jacobsen S, Ndeupen S. Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr Opin Virol. 2021;48:65\u201372.","journal-title":"Curr Opin Virol"},{"issue":"1","key":"2645_CR102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","volume":"31","author":"R-M Lu","year":"2024","unstructured":"Lu R-M, Hsu H-E, Perez SJLP, Kumari M, Chen G-H, Hong M-H, et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. J Biomed Sci. 2024;31(1):89.","journal-title":"J Biomed Sci"},{"key":"2645_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123012","volume":"640","author":"R Maharjan","year":"2023","unstructured":"Maharjan R, Hada S, Lee JE, Han H-K, Kim KH, Seo HJ, et al. Comparative study of lipid nanoparticle-based mRNA vaccine bioprocess with machine learning and combinatorial artificial neural network-design of experiment approach. Int J Pharm. 2023;640: 123012.","journal-title":"Int J Pharm"},{"key":"2645_CR104","doi-asserted-by":"publisher","first-page":"1042720","DOI":"10.3389\/fmolb.2022.1042720","volume":"9","author":"AA Metwally","year":"2022","unstructured":"Metwally AA, Nayel AA, Hathout RM. In silico prediction of siRNA ionizable-lipid nanoparticles in vivo efficacy: machine learning modeling based on formulation and molecular descriptors. Front Mol Biosci. 2022;9:1042720.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2645_CR105","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","volume":"15","author":"Y Xu","year":"2024","unstructured":"Xu Y, Ma S, Cui H, Chen J, Xu S, Gong F, et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat Commun. 2024;15(1):6305.","journal-title":"Nat Commun."},{"issue":"5","key":"2645_CR106","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ymthe.2022.04.004","volume":"30","author":"RE Young","year":"2022","unstructured":"Young RE, Hofbauer SI, Riley RS. Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines. Mol Ther. 2022;30(5):1792\u20133.","journal-title":"Mol Ther"},{"key":"2645_CR107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2022.03.009","volume":"25","author":"A Gerhardt","year":"2022","unstructured":"Gerhardt A, Voigt E, Archer M, Reed S, Larson E, Van Hoeven N, et al. A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery. Mol Ther Methods Clin Dev. 2022;25:205\u201314.","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"2645_CR108","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","volume":"9","author":"L Ai","year":"2023","unstructured":"Ai L, Li Y, Zhou L, Yao W, Zhang H, Hu Z, et al. Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2. Cell Discov. 2023;9(1):9.","journal-title":"Cell Discov"},{"issue":"1","key":"2645_CR109","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41541-023-00732-9","volume":"8","author":"M Li","year":"2023","unstructured":"Li M, Jia L, Xie Y, Ma W, Yan Z, Liu F, et al. Lyophilization process optimization and molecular dynamics simulation of mRNA-LNPs for SARS-CoV-2 vaccine. NPJ Vaccines. 2023;8(1):153.","journal-title":"NPJ Vaccines"},{"issue":"5","key":"2645_CR110","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","volume":"30","author":"G Maruggi","year":"2022","unstructured":"Maruggi G, Mallett CP, Westerbeck JW, Chen T, Lofano G, Friedrich K, et al. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. Mol Ther. 2022;30(5):1897\u2013912.","journal-title":"Mol Ther"},{"issue":"11","key":"2645_CR111","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","volume":"20","author":"LS Kristensen","year":"2019","unstructured":"Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019;20(11):675\u201391.","journal-title":"Nat Rev Genet"},{"issue":"10","key":"2645_CR112","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185(10):1728-44.e16.","journal-title":"Cell"},{"key":"2645_CR113","doi-asserted-by":"publisher","first-page":"1426129","DOI":"10.3389\/fmolb.2024.1426129","volume":"11","author":"R Lenk","year":"2024","unstructured":"Lenk R, Kleindienst W, Szab\u00f3 GT, Baiersd\u00f6rfer M, Boros G, Keller JM, et al. Understanding the impact of in vitro transcription byproducts and contaminants. Front Mol Biosci. 2024;11:1426129.","journal-title":"Front Mol Biosci"},{"issue":"9","key":"2645_CR114","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1093\/nar\/gkz208","volume":"47","author":"L Jin","year":"2019","unstructured":"Jin L, Song H, Tropea JE, Needle D, Waugh DS, Gu S, et al. The molecular mechanism of dsRNA processing by a bacterial Dicer. Nucleic Acids Res. 2019;47(9):4707\u201320. https:\/\/doi.org\/10.1093\/nar\/gkz208.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"2645_CR115","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/vaccines12050478","volume":"12","author":"Z Zhuang","year":"2024","unstructured":"Zhuang Z, Zhuo J, Yuan Y, Chen Z, Zhang S, Zhu A, et al. Harnessing T-cells for enhanced vaccine development against viral infections. Vaccines. 2024;12(5):478.","journal-title":"Vaccines"},{"issue":"1","key":"2645_CR116","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","volume":"21","author":"BM Warner","year":"2024","unstructured":"Warner BM, Safronetz D, Stein DR. Current perspectives on vaccines and therapeutics for Lassa Fever. Virol J. 2024;21(1):320.","journal-title":"Virol J."},{"issue":"1","key":"2645_CR117","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1038\/s41467-023-41376-6","volume":"14","author":"AJ Ronk","year":"2023","unstructured":"Ronk AJ, Lloyd NM, Zhang M, Atyeo C, Perrett HR, Mire CE, et al. A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nat Commun. 2023;14(1):5603.","journal-title":"Nat Commun"},{"issue":"4","key":"2645_CR118","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/QAD.0b013e32834f33e8","volume":"26","author":"E Van Gulck","year":"2012","unstructured":"Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VFI, Van De Velde A, Smits E, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS. 2012;26(4):F1\u201312.","journal-title":"AIDS"},{"issue":"12","key":"2645_CR119","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","volume":"27","author":"P Zhang","year":"2021","unstructured":"Zhang P, Narayanan E, Liu Q, Tsybovsky Y, Boswell K, Ding S, et al. A multiclade env\u2013gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat Med. 2021;27(12):2234\u201345.","journal-title":"Nat Med"},{"issue":"12","key":"2645_CR120","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41591-021-01573-6","volume":"27","author":"A August","year":"2021","unstructured":"August A, Attarwala HZ, Himansu S, Kalidindi S, Lu S, Pajon R, et al. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus. Nat Med. 2021;27(12):2224\u201333.","journal-title":"Nat Med"},{"issue":"26","key":"2645_CR121","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1016\/j.vaccine.2023.04.064","volume":"41","author":"CA Shaw","year":"2023","unstructured":"Shaw CA, August A, Bart S, Booth P-GJ, Knightly C, Brasel T, et al. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine. 2023;41(26):3898\u2013906.","journal-title":"Vaccine"},{"issue":"2","key":"2645_CR122","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.virs.2022.01.032","volume":"37","author":"N Ge","year":"2022","unstructured":"Ge N, Sun J, Liu Z, Shu J, Yan H, Kou Z, et al. An mRNA vaccine encoding Chikungunya virus E2\u2013E1 protein elicits robust neutralizing antibody responses and CTL immune responses. Virologica Sinica. 2022;37(2):266\u201376.","journal-title":"Virologica Sinica"},{"issue":"7644","key":"2645_CR123","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543(7644):248\u201351.","journal-title":"Nature"},{"key":"2645_CR124","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijid.2023.01.033","volume":"129","author":"BB Salgado","year":"2023","unstructured":"Salgado BB, Mau\u00e9s FCDJ, Jord\u00e3o M, Pereira RL, Toledo-Teixeira DA, Parise PL, et al. Antibody cross-reactivity and evidence of susceptibility to emerging Flaviviruses in the dengue-endemic Brazilian Amazon. Int J Infect Dis. 2023;129:142\u201351.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"2645_CR125","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s42003-023-05661-w","volume":"7","author":"GM Salem","year":"2024","unstructured":"Salem GM, Galula JU, Wu S-R, Liu J-H, Chen Y-H, Wang W-H, et al. Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus. Commun Biol. 2024;7(1):15.","journal-title":"Commun Biol."},{"issue":"5","key":"2645_CR126","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","volume":"23","author":"B Essink","year":"2023","unstructured":"Essink B, Chu L, Seger W, Barranco E, Le Cam N, Bennett H, et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect Dis. 2023;23(5):621\u201333.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"2645_CR127","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.3390\/v14081684","volume":"14","author":"W-C Wang","year":"2022","unstructured":"Wang W-C, Sayedahmed EE, Sambhara S, Mittal SK. Progress towards the development of a universal influenza vaccine. Viruses. 2022;14(8):1684.","journal-title":"Viruses"},{"key":"2645_CR128","doi-asserted-by":"publisher","first-page":"1381508","DOI":"10.3389\/fimmu.2024.1381508","volume":"15","author":"EP Mazunina","year":"2024","unstructured":"Mazunina EP, Gushchin VA, Kleymenov DA, Siniavin AE, Burtseva EI, Shmarov MM, et al. Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response. Front Immunol. 2024;15:1381508.","journal-title":"Front Immunol"},{"issue":"3","key":"2645_CR129","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.arbres.2024.01.004","volume":"60","author":"E Redondo","year":"2024","unstructured":"Redondo E, Rivero-Calle I, Mascar\u00f3s E, Oca\u00f1a D, Jimeno I, Gil \u00c1, et al. Respiratory syncytial virus vaccination recommendations for adults aged 60 years and older: the NeumoExperts Prevention Group position paper. Arch Bronconeumol. 2024;60(3):161\u201370.","journal-title":"Arch Bronconeumol"},{"issue":"1","key":"2645_CR130","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41541-020-0163-z","volume":"5","author":"AS Espeseth","year":"2020","unstructured":"Espeseth AS, Cejas PJ, Citron MP, Wang D, Distefano DJ, Callahan C, et al. Modified mRNA\/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection. Npj Vaccines. 2020;5(1):16.","journal-title":"Npj Vaccines."},{"issue":"2","key":"2645_CR131","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/cei.13517","volume":"202","author":"JS Tregoning","year":"2020","unstructured":"Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm N-M, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020;202(2):162\u201392.","journal-title":"Clin Exp Immunol"},{"key":"2645_CR132","doi-asserted-by":"crossref","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase 1\/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. medRxiv. 2020:2020.06.30.20142570.","DOI":"10.1101\/2020.06.30.20142570"},{"issue":"4","key":"2645_CR133","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","author":"D Laczk\u00f3","year":"2020","unstructured":"Laczk\u00f3 D, Hogan MJ, Toulmin SA, Hicks P, Lederer K, Gaudette BT, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity. 2020;53(4):724-32.e7.","journal-title":"Immunity"},{"issue":"2","key":"2645_CR134","doi-asserted-by":"publisher","first-page":"2234784","DOI":"10.1080\/21645515.2023.2234784","volume":"19","author":"AEG Ralise","year":"2023","unstructured":"Ralise AEG, Camargo TM, Marson FAL. Phase 4 clinical trials in the era of the Coronavirus Disease (COVID-19) pandemic and their importance to optimize the COVID-19 vaccination. Hum Vaccines Immunother. 2023;19(2):2234784.","journal-title":"Hum Vaccines Immunother"},{"key":"2645_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01963","author":"S Rauch","year":"2018","unstructured":"Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.01963.","journal-title":"Front Immunol"}],"updated-by":[{"DOI":"10.1186\/s12985-025-02880-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000}}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02645-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02645-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02645-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T11:30:36Z","timestamp":1757158236000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02645-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":135,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2645"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02645-6","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The paragraph beginning with \"The second and more advanced approach is ......... stability and translational activity.\" appears twice consecutively in the article and has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12985-025-02880-x","URL":"https:\/\/doi.org\/10.1186\/s12985-025-02880-x","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}